IsraGene, Haifa, Israel ; Cabernet Pharmaceuticals, R. David Thomas Center, One Science Drive, BOX 90344, Durham, NC 27708 USA.
EPMA J. 2010 Jun;1(2):317-27. doi: 10.1007/s13167-010-0020-7. Epub 2010 Jun 9.
Multiple sclerosis (MS) is a chronic autoimmune disease, where T-cells attack the myelin sheath in the central nervous system (CNS), characterized by relapsing-remitting episodes, or gradually increasing severity of symptoms and disability that accumulate over time. While current MS therapies have been proven in clinical trials to provide significant benefits, they cater only to subsets of patients. Moreover, there is an acute need to identify the most effective and safe treatment appropriate for each patient prospectively, since early intervention has been proven to prevent accumulation of irreversible dysfunction. In this review we discuss the current state-of-the-art in pharmacogenetic research as applied to the common marketed and in-development MS treatments, with respect to both efficacy and safety aspects. We conclude by discussing the relevance of pharmacogenetics and other biomarkers to the prediction, prevention and personalization of MS medications in the horizon.
多发性硬化症 (MS) 是一种慢性自身免疫性疾病，其中 T 细胞攻击中枢神经系统 (CNS) 中的髓鞘，其特征是反复发作或逐渐加重的症状和残疾，随着时间的推移而累积。虽然目前的 MS 疗法已在临床试验中被证明具有显著益处，但它们仅适用于患者的亚组。此外，迫切需要前瞻性地确定最有效和安全的治疗方法，因为已证明早期干预可防止不可逆功能障碍的积累。在这篇综述中，我们讨论了应用于常见的市售和正在开发的 MS 治疗方法的药物遗传学研究的最新进展，涉及疗效和安全性方面。最后，我们讨论了药物遗传学和其他生物标志物与 MS 药物的预测、预防和个性化的相关性。
